Dogwood Therapeutics Inc (DWTX) Stock Price, Quote & News

Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 620 8655

Website: dwtx.com

Address:

44 Milton Avenue, Alpharetta, United States

Drainomight Nov. 25 at 10:47 PM

$DWTX new filing = more shares outstanding

0 · Reply

joaneegell Nov. 24 at 2:24 PM

$DWTX thought we'd have a prolonged stiff increase but apparently what happened over the weekend was just morning wood

0 · Reply

TwongStocks Nov. 21 at 8:40 PM

$DWTX NASDAQ Equity Corporate Actions Alert # 2025 - 627 Information Regarding the Business Combination of Dogwood Therapeutics, Inc. (DWTX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-627 The business combination of Dogwood Therapeutics, Inc. (DWTX) and Wex Pharmaceuticals, Inc., a wholly owned subsidiary of CK Life Sciences Int’l. resulting in a Change of Control closed today, Friday, November 21, 2025. The name, symbol, and CUSIP number of the combined company will remain the same. These actions will become effective on Monday, November 24, 2025.

0 · Reply

Azlvr Nov. 21 at 7:49 PM

$DWTX 🤧 https://www.trustpilot.com/review/www.jccapitalconsultants.com

0 · Reply

SmallCapAlert Nov. 21 at 12:59 PM

$PRZO Watchlist: $PRZO ParaZero Successfully Achieved 100% Effectiveness https://parazero.com/2025/07/07/parazero-successfully-achieved-100-effectiveness-against-fast-incoming-drone-threats-in-live-field-demonstration/ Marketcap: $25 million $IZEA Marketcap: $100 million $XERS Marketcap: $1180 million $DWTX Marketcap: $15 million $SOS Marketcap: $106 million

0 · Reply

The1Albatross Nov. 18 at 11:25 PM

$DWTX ;)

0 · Reply

DandyTrades Nov. 18 at 2:21 PM

$GLMD $DWTX

0 · Reply

johnny6nine Nov. 18 at 2:20 PM

$GLMD break 1.65 and send it to the moon! $20+ dollar run like $DWTX earlier this year

0 · Reply

ByBi Nov. 11 at 12:59 PM

$DWTX Where are my imc's ?? Why no partnership update on imc1 ? Did they just discarded this pipeline ?

0 · Reply

ZacksSCR Nov. 10 at 5:20 PM

$DWTX: Interim Readout for Halneuron® Phase 2b Trial in CINP in 4Q25… https://buff.ly/zDd83ic

0 · Reply

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

Nov 6, 2025, 8:45 AM EST - 19 days ago

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 9:15 AM EDT - 26 days ago

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 14, 2025, 8:45 AM EDT - 6 weeks ago

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Oct 7, 2025, 8:45 AM EDT - 7 weeks ago

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

Sep 29, 2025, 12:17 PM EDT - 2 months ago

Dogwood Therapeutics, Inc. - Special Call

Sep 29, 2025, 7:15 AM EDT - 2 months ago

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Sep 3, 2025, 9:15 AM EDT - 2 months ago

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 9:00 AM EDT - 3 months ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 1:08 PM EDT - 3 months ago

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Aug 6, 2025, 9:15 AM EDT - 3 months ago

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Jun 3, 2025, 9:15 AM EDT - 6 months ago

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

May 8, 2025, 9:00 AM EDT - 7 months ago

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

May 1, 2025, 8:30 AM EDT - 7 months ago

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 11, 2025, 9:15 AM EDT - 8 months ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 3, 2025, 9:00 AM EDT - 8 months ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Mar 31, 2025, 3:45 PM EDT - 8 months ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 18, 2025, 8:45 AM EDT - 9 months ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 13, 2025, 9:00 AM EDT - 9 months ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 7, 2024, 7:05 AM EDT - 1 year ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Aug 8, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 9:41 AM EDT - 1 year ago

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jul 23, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

May 22, 2024, 1:30 PM EDT - 1 year ago

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 19, 2024, 8:53 PM EDT - 1 year ago

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17, 2024, 4:10 PM EDT - 1 year ago

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 11, 2024, 11:44 PM EDT - 1 year ago

Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:45 AM EDT - 1 year ago

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Mar 26, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Feb 29, 2024, 9:15 AM EST - 1 year ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 9:15 AM EST - 1 year ago

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Jan 22, 2024, 9:00 AM EST - 2 years ago

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 2, 2024, 7:05 AM EST - 2 years ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Nov 13, 2023, 11:21 AM EST - 2 years ago

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Oct 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Sep 18, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Aug 14, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 10, 2023, 10:05 AM EDT - 2 years ago

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 9, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Jul 17, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

May 25, 2023, 4:05 PM EDT - 2 years ago

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

May 11, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces First Quarter 2023 Financial Results

May 4, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Drainomight Nov. 25 at 10:47 PM

$DWTX new filing = more shares outstanding

0 · Reply

joaneegell Nov. 24 at 2:24 PM

$DWTX thought we'd have a prolonged stiff increase but apparently what happened over the weekend was just morning wood

0 · Reply

TwongStocks Nov. 21 at 8:40 PM

0 · Reply

Azlvr Nov. 21 at 7:49 PM

$DWTX 🤧 https://www.trustpilot.com/review/www.jccapitalconsultants.com

0 · Reply

SmallCapAlert Nov. 21 at 12:59 PM

0 · Reply

The1Albatross Nov. 18 at 11:25 PM

$DWTX ;)

0 · Reply

DandyTrades Nov. 18 at 2:21 PM

$GLMD $DWTX

0 · Reply

johnny6nine Nov. 18 at 2:20 PM

$GLMD break 1.65 and send it to the moon! $20+ dollar run like $DWTX earlier this year

0 · Reply

ByBi Nov. 11 at 12:59 PM

$DWTX Where are my imc's ?? Why no partnership update on imc1 ? Did they just discarded this pipeline ?

0 · Reply

ZacksSCR Nov. 10 at 5:20 PM

$DWTX: Interim Readout for Halneuron® Phase 2b Trial in CINP in 4Q25… https://buff.ly/zDd83ic

0 · Reply

AllAmerican82ndAirborne Nov. 6 at 12:32 AM

$DWTX Board is silent…. what will earnings bring us?

0 · Reply

Drainomight Oct. 31 at 9:40 AM

$DWTX

0 · Reply

The1Albatross Oct. 30 at 4:35 PM

$DWTX Full position by mid NOV Play comes to us. Not the other way around

3 · Reply

BillionerOfKing Oct. 30 at 3:53 PM

$DWTX Current Stock Price: $6.37 No options data available.

0 · Reply

Love_To_Learn Oct. 30 at 12:00 AM

$DWTX $TNXP made a change just b4 close

0 · Reply

The1Albatross Oct. 28 at 6:43 PM

$DWTX Already 20%

1 · Reply

tboykeyhoang Oct. 27 at 6:09 PM

$DWTX the trading volume is going up in the last two days. Could it be a signal for something more?

0 · Reply

jamersonmoody Oct. 26 at 5:14 AM

$DWTX see you at $5

0 · Reply

Drainomight Oct. 24 at 7:38 PM

$DWTX loaded up

0 · Reply

HeyHoser Oct. 24 at 1:05 PM

$DWTX $5.3 support, adds down here. $4's are welcome

1 · Reply

The1Albatross Oct. 21 at 3:12 PM

$DWTX Dozens of limits - few stinkies if it gets cheeky Big play to finish/start the year

2 · Reply

Arcides Oct. 14 at 12:58 PM

$DWTX from 11.08 on sep 29 premarket high to close the gap at 5.80, complete piece of shit.

1 · Reply

Market Cap	14.54M
Revenue (ttm)	0.00
Net Income (ttm)	-12.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	26,300
Avg Vol	949,518
Day's Range	N/A - N/A
Shares Out	2.29M
Stochastic %K	95%
Beta	1.86
Analysts	Strong Sell
Price Target	$18.33